SCHEMBL408920

SCHEMBL408920

CNc1c(C)c(=O)c1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL409685 0.79
SCHEMBL14595188 0.73
SCHEMBL13808869 0.69
SCHEMBL14203250 0.69 GRIN2D (0.37)
SCHEMBL8229788 0.69 CXCR2 (0.33)
SCHEMBL13887506 0.69 KDM4E (0.34)
SCHEMBL8368736 0.69 KDM4E (0.31)
SCHEMBL463072 0.67
SCHEMBL791197 0.67
SCHEMBL2874352 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024020346-A2 GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2024-01-25 WO disclosed
WO-2023240261-A1 NUCLEOBASE EDITING SYSTEM AND METHOD OF USING SAME FOR MODIFYING NUCLEIC ACID SEQUENCES RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-12-14 WO disclosed
WO-2023196931-A1 CYCLIC LIPIDS AND LIPID NANOPARTICLES (LNP) FOR THE DELIVERY OF NUCLEIC ACIDS OR PEPTIDES FOR USE IN VACCINATING AGAINST INFECTIOUS AGENTS RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-10-12 WO disclosed
WO-2021231963-A1 RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION, AND METHODS OF USING THE SAME FOR TREATING COVID-19 MODERNATX, INC. (US) 2021-11-18 WO disclosed
US-9925209-B2 Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) 2018-03-27 US disclosed
US-20170217963-A1 SPHINOGOSINE-1-PHOSPHATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS THE SCRIPPS RESEARCH INSTITUTE 2017-08-03 US disclosed
US-9486497-B2 Treatment of immunocompromised conditions THE UNIVERSITY OF QUEENSLAND (AU) 2016-11-08 US disclosed
US-20160193294-A1 COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2016-07-07 US disclosed
US-20150118185-A1 Heparosan-Polypeptide and Heparosan-Polynucleotide Drug Conjugates and Methods of Making and Using Same THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA 2015-04-30 US disclosed
US-8986650-B2 Complex folate-NOTA-Ga68 GUERBET (FR) 2015-03-24 US disclosed
EP-1663245-B1 CEPHEM COMPOUNDS ASTELLAS PHARMA INC (JP) 2010-04-07 EP disclosed
US-20090214441-A1 Lipophilic Chelates and Their Use in Imaging GUERBET (FR) 2009-08-27 US disclosed
US-7566718-B2 Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity SCHERING CORPORATION (US) 2009-07-28 US disclosed
US-20090169479-A1 Compounds Comprising Short Aminoalcohol Chains and Metal Complexes for Medical Imgaing GUERBET (FR) 2009-07-02 US disclosed
US-7524852-B2 Bicyclic pyrimidine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-04-28 US disclosed
US-7524852-B2 Bicyclic pyrimidine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-04-28 US disclosed
US-7192943-B2 Cephem compounds ASTELLAS PHARMA INC. (JP) 2007-03-20 US disclosed
US-7192943-B2 Cephem compounds ASTELLAS PHARMA INC. (JP) 2007-03-20 US disclosed
US-20070054919-A1 Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity SCHERING CORPORATION 2007-03-08 US disclosed
US-20070021611-A1 Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity SCHERING CORPORATION 2007-01-25 US disclosed